Table 1.

Selected Chk1 inhibitors in preclinical or clinical development

Compound name	Company	Other targets	Phase of development	Reference
AZD7762	AstraZeneca	CDK1, Chk2, CAMK, SRC-like kinase	Discontinued	[76–78]
SCH900776/ MK-8776	Merck	Pim1	Phase II	[72, 73] http://www.clinicaltrials.gov
IC83/ LY2603618	Ely Lilly	Undisclosed	Phase I/II with pemetredex and cisplatin	http://www.clinicaltrials.gov
LY2606368	Ely Lilly	Chk2	Phase I	http://www.clinicaltrials.gov
GDC-0425	Genentech	Undisclosed	Phase I	http://www.clinicaltrials.gov
PF-00477736	Pfizer	Chk2, VEGFR2, Fms, Yes, Flt3, Ret	Discontinued	[79]
XL844	Exelixis	Chk2	Discontinued	http://www.clinicaltrials.gov
CEP-3891	Cephalon	Undisclosed	Preclinical	[80]
SAR-020106	Sareum	Undisclosed	Preclinical	[17]
CCT-244747	Sareum	FLT3, Chk2, CDK1	Preclinical	[81]
Arry-575	Array	Undisclosed	Preclinical	http://www.arraybiopharma.com